Genflow Completes Dosing Phase of Canine Gene Therapy Trial

Core Viewpoint - Genflow Biosciences has successfully completed the dosing phase of its canine gene therapy trial, with no adverse events reported, indicating a strong safety profile for the investigational SIRT6-based therapy [1][2]. Group 1: Trial Progress and Safety - All dogs enrolled in the clinical trial have received the full administration of the gene therapy without any reported adverse events, demonstrating a strong safety and tolerability profile [1][2]. - The trial is a blinded study, and efficacy outcomes will be assessed in mid-to-late January 2026, which will include blood analyses and muscle biopsies to evaluate therapeutic benefits related to sarcopenia and healthspan biomarkers [3]. - The dogs will be monitored for a total duration of 180 days, with a second efficacy assessment planned at the six-month mark, expected to yield results in June-July 2026 [4]. Group 2: Future Plans and Licensing - Following the analysis of efficacy data, Genflow plans to resume discussions with various animal health companies to explore potential early-stage licensing opportunities [5]. - Dr. Eric Leire, CEO of Genflow, emphasized the significance of these milestones for the longevity program and expressed anticipation for sharing initial efficacy data in the coming months [6]. Group 3: Company Background - Genflow Biosciences, founded in 2020 and headquartered in the UK, focuses on pioneering gene therapies aimed at decelerating the aging process and promoting longer, healthier lives [7]. - The company's lead compound, GF-1002, utilizes a centenarian variant of the SIRT6 gene, which has shown promising preclinical results [7].